US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

F/m Emerald Life Sciences Innovation ETF

43.38

-0.0220-0.05%

Volume:222

Turnover:9.62K

Market Cap:120.47M

PE:- -

High:43.38

Open:43.38

Low:43.38

Close:43.40

52wk High:48.78

52wk Low:29.44

Shares:2.78M

Float Shares:2.78M

Volume Ratio:0.28

T/O Rate:0.01%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Barclays downgrades Scholar Rock on valuation after FDA approval

Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20

LivaNova Director Francesco Bianchi Sells 3,500 Shares for $273,032.20

Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027

THOMSON REUTERS

Biofrontera announces FDA approval of Ameluz supplemental new drug application

Scholar Rock Wins FDA Approval for SMA Therapy

Scholar Rock price target raised to $84 from $76 at BMO Capital

Telix Wins FDA Nod for First FET-PET Glioma Imaging Drug Pixclara

Scholar Rock announces FDA approval of isembyld

Travere Therapeutics Grants Inducement RSUs Covering 56,220 Shares to 16 New Employees

Travere Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS

Travere Therapeutics Director Jeffrey A. Meckler Disposes of Common Shares Worth $1.31 Million

Pharming wins FDA nod to extend Joenja use to younger APDS children

Wall Street Analysts Are Bullish on Top Healthcare Picks

UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating

MT Newswires Live

LivaNova Director Brooke Story Sells 2,300 Shares for $187,270.14

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)

Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis

MT Newswires Live

Video: Novartis slides after second recent drug development setback

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/LFSC/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"LFSC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","market":"US","secType":"STK","nameCN":"F/m Emerald Life Sciences Innovation ETF","latestPrice":43.379,"timestamp":1791216627693,"preClose":43.401,"halted":0,"volume":222,"delay":0,"changeRate":-0.0005069007626553667,"floatShares":2777035,"shares":2777035,"eps":0,"marketStatus":"Trading","change":-0.022,"latestTime":"10-05 12:12:30 EDT","open":43.379,"high":43.379,"low":43.379,"amount":9620.089392,"amplitude":0,"askPrice":43.66,"askSize":200,"bidPrice":43.45,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791230400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":43.401,"sharesOutstanding":2657035,"nav":43.44,"aum":120634400.4,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":43.34,"preClose":43.401,"latestTime":"19:30 EDT","volume":10,"amount":433.284,"timestamp":1790983803387,"change":-0.061,"changeRate":-0.001405,"amplitude":0},"volumeRatio":0.278243},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LFSC\",,,,,undefined,":{"symbol":"LFSC","floatShares":2777035,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.278243,"shares":2777035,"dividePrice":0,"high":43.379,"amplitude":0,"preClose":43.401,"low":43.379,"week52Low":29.4441,"pbRate":"--","week52High":48.78,"institutionHeld":0,"latestPrice":43.379,"eps":0,"divideRate":0,"volume":222,"delay":0,"ttmEps":0,"open":43.379,"prevYearClose":36.6147,"prevWeekClose":43.401,"prevMonthClose":44.5697,"prevQuarterClose":44.5697,"fiveDayClose":44.545,"twentyDayClose":46.1341,"sixtyDayClose":46.2892},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LFSC\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LFSC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LFSC\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LFSC\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667643557","title":"Barclays downgrades Scholar Rock on valuation after FDA approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2667643557","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667643557?lang=en_us&edition=fundamental","pubTime":"2026-09-15 17:10","pubTimestamp":1789463419,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout downgraded Scholar Rock (SRRK) to Equal Weight from Overweight with a price target of $58, up from $55. The approval ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/barclays-downgrades-scholar-rock-on-valuation-after-fda-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/barclays-downgrades-scholar-rock-on-valuation-after-fda-approval-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","CDIG","LABU","NVIB","IDNA","LFSC","MEDI","MRNY","GNMX","RSPH","TACU","IEIH","FRTY","GDOC","TBXU","XLVX","TSPA","BBP","PSCH","PINK","SYNB","IYH","BMED","TECB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667569983","title":"Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2667569983","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667569983?lang=en_us&edition=fundamental","pubTime":"2026-09-15 06:12","pubTimestamp":1789423938,"startTime":"0","endTime":"0","summary":"Guardant Health CIO Kumud Kalia disposes of 4,000 common shares worth $632,193.20Guardant Health Chief Information Officer Kumud Kalia sold 4,000 common shares on Sept. 11, 2026.The sale price was USD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL3DVtS3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health CIO Kumud Kalia Disposes of 4,000 Common Shares Worth $632,193.20","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFOX","GNOM","LU0889565916.HKD","LFSC","BK4585","BK4588","GDOC","PTH","GNMX","LU0320765992.SGD","GH","LU0109394709.USD","BK4551","EKG","BK4196","HELX","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695583","title":"LivaNova Director Francesco Bianchi Sells 3,500 Shares for $273,032.20","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695583","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695583?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:24","pubTimestamp":1789417453,"startTime":"0","endTime":"0","summary":"LivaNova director Francesco Bianchi sells 3,500 shares for $273,032.20LivaNova director Francesco Bianchi sold 3,500 ordinary shares on Sep. 10, 2026 at USD 78.01 per share.Direct holdings fell to 4,4","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nNDL6ygSL8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"LivaNova Director Francesco Bianchi Sells 3,500 Shares for $273,032.20","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","LU2065170008.USD","LU2065169927.USD","LIVN","BK4082","LU2065171311.SGD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667087693","title":"Guardant Health, - Evicore by Evernorth to Cover Shield Blood Test for Crc Screening Effective Jan 1, 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2667087693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667087693?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:07","pubTimestamp":1789416443,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nFWN4560HZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4196","BK4588","GDOC","BK4551","EKG","PTH","BK4535","GNOM","GNMX","LFSC","LU0109394709.USD","LU0889565916.HKD","GH","LU0320765992.SGD","BK4585","FFOX","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667661630","title":"Biofrontera announces FDA approval of Ameluz supplemental new drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2667661630","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667661630?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:35","pubTimestamp":1789392922,"startTime":"0","endTime":"0","summary":"Biofrontera (BFRI) announced that the FDA has approved the company’s supplemental new drug application, or sNDA, for Ameluz topical gel, 10%, in co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biofrontera-announces-fda-approval-of-ameluz-supplemental-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biofrontera-announces-fda-approval-of-ameluz-supplemental-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FRTY","MRNY","GDOC","IDNA","MEDI","PSCH","IEIH","LABU","XLVX","BK4585","LFSC","SYNB","GNMX","TECB","PINK","BK4007","BFRI","TBXU","IBB","IYH","BBP","BK4588","BMED","RSPH","NVIB","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667066661","title":"Scholar Rock Wins FDA Approval for SMA Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2667066661","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667066661?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:32","pubTimestamp":1789389127,"startTime":"0","endTime":"0","summary":"The latest update is out from Scholar Rock Holding ( ($SRRK) ). On September 11, 2026, Scholar Rock announced U.S. FDA approval of ISEMBYLD (apiteg...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PINK","IEIH","RSPH","IDNA","LABU","MRNX","GNMX","NVIB","TECB","MEDI","FRTY","SYNB","XLVX","PSCH","BK4585","GDOC","MRNY","BMED","BBP","LFSC","IBB","TBXU","IYH","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667134663","title":"Scholar Rock price target raised to $84 from $76 at BMO Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2667134663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667134663?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:36","pubTimestamp":1789385772,"startTime":"0","endTime":"0","summary":"BMO Capital raised the firm’s price target on Scholar Rock (SRRK) to $84 from $76 and keeps an Outperform rating on the shares. The FDA approval of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","TECB","BMED","LABU","IEIH","THNR","SYNB","GNMX","XLVX","IYH","NVIB","PINK","MEDI","BBP","MRNY","BK4585","IBRN","BK4139","IDNA","LFSC","MRNX","SRRK","RSPH","BK4588","GDOC","PSCH","FRTY","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667635862","title":"Telix Wins FDA Nod for First FET-PET Glioma Imaging Drug Pixclara","url":"https://stock-news.laohu8.com/highlight/detail?id=2667635862","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667635862?lang=en_us&edition=fundamental","pubTime":"2026-09-14 06:54","pubTimestamp":1789340092,"startTime":"0","endTime":"0","summary":"The latest update is out from Telix Pharmaceuticals ( ($AU:TLX) ). Telix Pharmaceuticals has secured U.S. FDA approval for Pixclara, the first FET-...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-wins-fda-nod-for-first-fet-pet-glioma-imaging-drug-pixclara?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-wins-fda-nod-for-first-fet-pet-glioma-imaging-drug-pixclara?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BMED","TECB","BBP","IYH","RSPH","MRNY","BK4139","LFSC","IEIH","XLVX","LABU","FET","GDOC","FRTY","GNMX","BK4585","BK4179","TBXU","PINK","SYNB","IBB","MRNX","NVIB","MEDI","TLX","PSCH","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666577803","title":"Scholar Rock announces FDA approval of isembyld","url":"https://stock-news.laohu8.com/highlight/detail?id=2666577803","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666577803?lang=en_us&edition=fundamental","pubTime":"2026-09-12 06:30","pubTimestamp":1789165818,"startTime":"0","endTime":"0","summary":"Scholar Rock (SRRK) announced that the FDA has approved isembyld for the treatment of spinal muscular atrophy in adults and children two years of a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBB","MRNX","GDOC","IYH","FRTY","IEIH","LFSC","SRRK","BK4139","TECB","MEDI","NVIB","TBXU","BK4585","LABU","THNR","SYNB","RSPH","IDNA","GNMX","PINK","PSCH","MRNY","BMED","BK4588","BBP","XLVX","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666216574","title":"Travere Therapeutics Grants Inducement RSUs Covering 56,220 Shares to 16 New Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2666216574","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666216574?lang=en_us&edition=fundamental","pubTime":"2026-09-12 05:00","pubTimestamp":1789160417,"startTime":"0","endTime":"0","summary":"Travere Therapeutics grants inducement RSUs covering 56,220 shares to 16 new employeesTravere Therapeutics granted inducement restricted stock units covering 56,220 common shares to 16 new employees o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL3z9S9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666574294","title":"Travere Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666574294","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666574294?lang=en_us&edition=fundamental","pubTime":"2026-09-12 05:00","pubTimestamp":1789160400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nTUA4L90NS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVTX","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666714225","title":"Travere Therapeutics Director Jeffrey A. Meckler Disposes of Common Shares Worth $1.31 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666714225","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666714225?lang=en_us&edition=fundamental","pubTime":"2026-09-12 04:06","pubTimestamp":1789157186,"startTime":"0","endTime":"0","summary":"Travere Therapeutics director Jeffrey A. Meckler disposes of common shares worth $1.31 millionTravere Therapeutics director Jeffrey A. Meckler exercised stock options on Sep. 10, 2026 for 20,000 commo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL7tql2w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Travere Therapeutics Director Jeffrey A. Meckler Disposes of Common Shares Worth $1.31 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVTX","BK4139","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666795715","title":"Pharming wins FDA nod to extend Joenja use to younger APDS children","url":"https://stock-news.laohu8.com/highlight/detail?id=2666795715","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666795715?lang=en_us&edition=fundamental","pubTime":"2026-09-12 02:32","pubTimestamp":1789151567,"startTime":"0","endTime":"0","summary":"Pharming Group ( ($NL:PHARM) ) has provided an announcement. Pharming has secured U.S. FDA approval for new 40 mg and 50 mg twice-daily doses of Jo...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pharming-wins-fda-nod-to-extend-joenja-use-to-younger-apds-children?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","BK4585","PINK","NVIB","PSCH","TBXU","BK4588","IBB","MRNY","SYNB","GDOC","GNMX","BMED","XLVX","LFSC","LABU","IYH","FRTY","MEDI","TECB","RSPH","BBP","IEIH","MRNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666853924","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2666853924","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666853924?lang=en_us&edition=fundamental","pubTime":"2026-09-09 22:40","pubTimestamp":1788964820,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Spyre Therapeutics (SYRE), Autolus Therapeutics (AUT...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-332?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-332?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","XBI","BK4585","BK4581","HCSG","BK4139","XLV","LU0128526141.USD","SYRE","LU0029874061.USD","LABU","BK4588","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666368655","title":"UBS Adjusts Guardant Health Price Target to $225 From $175, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666368655","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666368655?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:35","pubTimestamp":1788960920,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of buy and mean price target of $198.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LFSC","GNOM","LU0889565916.HKD","HELX","EKG","BK4551","GNMX","LU0109394709.USD","PTH","GH","FFOX","BK4588","BK4585","LU0320765992.SGD","BK4535","BK4196","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666370307","title":"LivaNova Director Brooke Story Sells 2,300 Shares for $187,270.14","url":"https://stock-news.laohu8.com/highlight/detail?id=2666370307","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666370307?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:02","pubTimestamp":1788901342,"startTime":"0","endTime":"0","summary":"LivaNova director Brooke Story sells 2,300 shares for $187,270.14LivaNova director Brooke Story sold 2,300 ordinary shares on Sep. 4, 2026 at USD 81.42 each.Direct holdings fell to 7,488 ordinary shar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL1gkKlF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"LivaNova Director Brooke Story Sells 2,300 Shares for $187,270.14","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LFSC","LU2065169927.USD","BK4082","LU2065171311.SGD","LIVN","LU2065170008.USD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MRNY","GDOC","IDNA","PSIL","MEDI","SURI","PSCH","PTH","IEIH","BIB","BBH","FBT","BME","FTXH","PBE","CNCR","GNOM","LFSC","PJP","SYNB","CANC","JHMH","CURE","GNMX","IBRN","MDTX","PINK","IBBJ","TBXU","IBB","GPCR","FXH","BBP","IBBQ","AZNH","MEDX","XPH","SBIO","HYLG","LLYX","MNTL","APXH","RSPH","NVIB","PBPH","WDNA","JDOC","GSKH","FHLC","HRTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374637","title":"Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374637","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666374637?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:20","pubTimestamp":1788888012,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Spyre Therapeutics (SYRE) and BioCryst (BCRX) with b...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spyre-therapeutics-syre-biocryst-bcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-spyre-therapeutics-syre-biocryst-bcrx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LFSC","SYRE","XLV","BK4139","BCRX","BK4137","BK4581","BK4585","BK4588","BK4547","HCSG","LABU","LU0128526141.USD","XBI","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375642","title":"Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375642","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375642?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:35","pubTimestamp":1788874514,"startTime":"0","endTime":"0","summary":"Spyre Therapeutics'  SPY003 met the primary endpoint in the phase 2 Skyline trial, reducing the Robarts Histopathology Index score by 10 points at week 12 in patients with moderately to severely active ulcerative colitis, the company said Tuesday.The anti-IL-23 therapy achieved a 20% clinical-remission rate, measured by modified Mayo Score, and a 30% endoscopic-improvement rate, while remaining well tolerated with a safety profile consistent with the IL-23 class, the company said.The results complete clinical proof-of-concept for all three components of Spyre's IBD strategy, with part B of the SKYLINE trial evaluating pairwise combinations now enrolling.Spyre expects topline SKYLINE part B induction data in 2027, with phase 2 SKYWAY results for SPY072 in psoriatic arthritis and axial spondyloarthritis expected in the fourth quarter of 2026, it added.Spyre Therapeutics shares were down 1.1% in premarket activity.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SYRE","BK4539","LENZ","LFSC","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665858375","title":"Video: Novartis slides after second recent drug development setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2665858375","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665858375?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:05","pubTimestamp":1788872716,"startTime":"0","endTime":"0","summary":"The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how the markets will open, which stocks will...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/video-novartis-slides-after-second-recent-drug-development-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/video-novartis-slides-after-second-recent-drug-development-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","FBT","LFSC"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}]}}